pser pkc substrate Search Results


phosphorylated ser pkc substrate  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc phosphorylated ser pkc substrate
Phosphorylated Ser Pkc Substrate, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phosphorylated ser pkc substrate/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
phosphorylated ser pkc substrate - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
polyclonal rabbit-anti-phosphorylated-ser cdks substrate  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc polyclonal rabbit-anti-phosphorylated-ser cdks substrate
Polyclonal Rabbit Anti Phosphorylated Ser Cdks Substrate, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/polyclonal rabbit-anti-phosphorylated-ser cdks substrate/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
polyclonal rabbit-anti-phosphorylated-ser cdks substrate - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
anti-pkc substrates (pser/pthr; cell signaling)  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc anti-pkc substrates (pser/pthr; cell signaling)
Anti Pkc Substrates (Pser/Pthr; Cell Signaling), supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-pkc substrates (pser/pthr; cell signaling)/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
anti-pkc substrates (pser/pthr; cell signaling) - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
anti-phospho-p38 mapk (ser 180 /tyr 182 ) polyclonal antibodies (pabs  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc anti-phospho-p38 mapk (ser 180 /tyr 182 ) polyclonal antibodies (pabs
Effects of VAS compounds on the PKC/NOX downstream signaling pathway. ( A ) Washed platelets (3.6 × 10 8 cells/ml) were pre-incubated with DMSO (solvent control), VAS compounds (2–10 μM), or Ro 31-8220 (2 μM) following stimulation with PDBu (150 nM) to trigger platelet aggregation. ( B ) The statistical analysis in ( A ). ( C ) After the reaction, platelet lysates were directly collected, and then subjected to Western blotting. Specific antibodies were used to detect PKC, IKKβ, and <t>p38</t> <t>MAPK.</t> ( D , E ) Luciferase/luciferin and FITC-P-selectin antibody were used to detect ATP release and P-selectin using a microplate reader and flow cytometry, respectively. Data ( B , D ) are presented as means ± S.E.M. ( n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001, compared with the DMSO (solvent control) group. Data ( C , E ) are presented as means ± SEM ( C , n = 4; E , n = 3). ***p < 0.001, compared with the resting group. ## p < 0.01 and ### p < 0.001, compared with the PDBu-treated (positive control) group. Comparisons were made by ANOVA.
Anti Phospho P38 Mapk (Ser 180 /Tyr 182 ) Polyclonal Antibodies (Pabs, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-phospho-p38 mapk (ser 180 /tyr 182 ) polyclonal antibodies (pabs/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
anti-phospho-p38 mapk (ser 180 /tyr 182 ) polyclonal antibodies (pabs - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
rabbit monoclonal phospho-pka substrate  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc rabbit monoclonal phospho-pka substrate
Activation <t>of</t> <t>PKC</t> or CaMKII, but not <t>PKA,</t> is required for the accumulation of SENP1 at synapses. a Representative confocal images of time-lapse recordings of GFP-SENP1-expressing rat hippocampal secondary dendrites preincubated 10 min in TTX (0.5 µM) with JNJ16259685 (0.5 µM) and either the PKC antagonist Chelerythrine (5 µM), the CaMKII antagonist KN93 (1 µM) or the PKA inhibitor H89 (1 µM) and treated in the same medium for 25 min with DHPG (50 µM) as indicated. Scale bar, 5 µm. b Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.171 ± 0.010) and [Chelerythrine + DHPG + JNJ16259685] (1.004 ± 0.018) conditions. c Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.168 ± 0.012) and [KN93 + JNJ16259685 + DHPG] (1.008 ± 0.012) conditions. d Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.142 ± 0.014) and [H89 + JNJ16259685 + DHPG] (1.072 ± 0.011) conditions. Statistics: Ordinary one-way ANOVA with Tukey post hoc test. p values are indicated on the bars. n.s. non-significant
Rabbit Monoclonal Phospho Pka Substrate, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit monoclonal phospho-pka substrate/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
rabbit monoclonal phospho-pka substrate - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
anti phospho marcks  (Cell Signaling Technology Inc)
94
Cell Signaling Technology Inc anti phospho marcks
Activation <t>of</t> <t>PKC</t> or CaMKII, but not <t>PKA,</t> is required for the accumulation of SENP1 at synapses. a Representative confocal images of time-lapse recordings of GFP-SENP1-expressing rat hippocampal secondary dendrites preincubated 10 min in TTX (0.5 µM) with JNJ16259685 (0.5 µM) and either the PKC antagonist Chelerythrine (5 µM), the CaMKII antagonist KN93 (1 µM) or the PKA inhibitor H89 (1 µM) and treated in the same medium for 25 min with DHPG (50 µM) as indicated. Scale bar, 5 µm. b Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.171 ± 0.010) and [Chelerythrine + DHPG + JNJ16259685] (1.004 ± 0.018) conditions. c Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.168 ± 0.012) and [KN93 + JNJ16259685 + DHPG] (1.008 ± 0.012) conditions. d Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.142 ± 0.014) and [H89 + JNJ16259685 + DHPG] (1.072 ± 0.011) conditions. Statistics: Ordinary one-way ANOVA with Tukey post hoc test. p values are indicated on the bars. n.s. non-significant
Anti Phospho Marcks, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 94/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti phospho marcks/product/Cell Signaling Technology Inc
Average 94 stars, based on 1 article reviews
anti phospho marcks - by Bioz Stars, 2026-02
94/100 stars
  Buy from Supplier
ser pkc substrate 6967s  (Cell Signaling Technology Inc)
95
Cell Signaling Technology Inc ser pkc substrate 6967s
Activation <t>of</t> <t>PKC</t> or CaMKII, but not <t>PKA,</t> is required for the accumulation of SENP1 at synapses. a Representative confocal images of time-lapse recordings of GFP-SENP1-expressing rat hippocampal secondary dendrites preincubated 10 min in TTX (0.5 µM) with JNJ16259685 (0.5 µM) and either the PKC antagonist Chelerythrine (5 µM), the CaMKII antagonist KN93 (1 µM) or the PKA inhibitor H89 (1 µM) and treated in the same medium for 25 min with DHPG (50 µM) as indicated. Scale bar, 5 µm. b Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.171 ± 0.010) and [Chelerythrine + DHPG + JNJ16259685] (1.004 ± 0.018) conditions. c Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.168 ± 0.012) and [KN93 + JNJ16259685 + DHPG] (1.008 ± 0.012) conditions. d Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.142 ± 0.014) and [H89 + JNJ16259685 + DHPG] (1.072 ± 0.011) conditions. Statistics: Ordinary one-way ANOVA with Tukey post hoc test. p values are indicated on the bars. n.s. non-significant
Ser Pkc Substrate 6967s, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 95/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/ser pkc substrate 6967s/product/Cell Signaling Technology Inc
Average 95 stars, based on 1 article reviews
ser pkc substrate 6967s - by Bioz Stars, 2026-02
95/100 stars
  Buy from Supplier
anti-phospho-serine antibodies  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc anti-phospho-serine antibodies
Activation <t>of</t> <t>PKC</t> or CaMKII, but not <t>PKA,</t> is required for the accumulation of SENP1 at synapses. a Representative confocal images of time-lapse recordings of GFP-SENP1-expressing rat hippocampal secondary dendrites preincubated 10 min in TTX (0.5 µM) with JNJ16259685 (0.5 µM) and either the PKC antagonist Chelerythrine (5 µM), the CaMKII antagonist KN93 (1 µM) or the PKA inhibitor H89 (1 µM) and treated in the same medium for 25 min with DHPG (50 µM) as indicated. Scale bar, 5 µm. b Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.171 ± 0.010) and [Chelerythrine + DHPG + JNJ16259685] (1.004 ± 0.018) conditions. c Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.168 ± 0.012) and [KN93 + JNJ16259685 + DHPG] (1.008 ± 0.012) conditions. d Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.142 ± 0.014) and [H89 + JNJ16259685 + DHPG] (1.072 ± 0.011) conditions. Statistics: Ordinary one-way ANOVA with Tukey post hoc test. p values are indicated on the bars. n.s. non-significant
Anti Phospho Serine Antibodies, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-phospho-serine antibodies/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
anti-phospho-serine antibodies - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
anti-phospho-(ser) pkc substrate antibody  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc anti-phospho-(ser) pkc substrate antibody
Activation <t>of</t> <t>PKC</t> or CaMKII, but not <t>PKA,</t> is required for the accumulation of SENP1 at synapses. a Representative confocal images of time-lapse recordings of GFP-SENP1-expressing rat hippocampal secondary dendrites preincubated 10 min in TTX (0.5 µM) with JNJ16259685 (0.5 µM) and either the PKC antagonist Chelerythrine (5 µM), the CaMKII antagonist KN93 (1 µM) or the PKA inhibitor H89 (1 µM) and treated in the same medium for 25 min with DHPG (50 µM) as indicated. Scale bar, 5 µm. b Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.171 ± 0.010) and [Chelerythrine + DHPG + JNJ16259685] (1.004 ± 0.018) conditions. c Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.168 ± 0.012) and [KN93 + JNJ16259685 + DHPG] (1.008 ± 0.012) conditions. d Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.142 ± 0.014) and [H89 + JNJ16259685 + DHPG] (1.072 ± 0.011) conditions. Statistics: Ordinary one-way ANOVA with Tukey post hoc test. p values are indicated on the bars. n.s. non-significant
Anti Phospho (Ser) Pkc Substrate Antibody, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti-phospho-(ser) pkc substrate antibody/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
anti-phospho-(ser) pkc substrate antibody - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
rabbit polyclonal anti-phospho-serine cdk substrate antibodies  (Cell Signaling Technology Inc)
90
Cell Signaling Technology Inc rabbit polyclonal anti-phospho-serine cdk substrate antibodies
Activation <t>of</t> <t>PKC</t> or CaMKII, but not <t>PKA,</t> is required for the accumulation of SENP1 at synapses. a Representative confocal images of time-lapse recordings of GFP-SENP1-expressing rat hippocampal secondary dendrites preincubated 10 min in TTX (0.5 µM) with JNJ16259685 (0.5 µM) and either the PKC antagonist Chelerythrine (5 µM), the CaMKII antagonist KN93 (1 µM) or the PKA inhibitor H89 (1 µM) and treated in the same medium for 25 min with DHPG (50 µM) as indicated. Scale bar, 5 µm. b Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.171 ± 0.010) and [Chelerythrine + DHPG + JNJ16259685] (1.004 ± 0.018) conditions. c Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.168 ± 0.012) and [KN93 + JNJ16259685 + DHPG] (1.008 ± 0.012) conditions. d Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.142 ± 0.014) and [H89 + JNJ16259685 + DHPG] (1.072 ± 0.011) conditions. Statistics: Ordinary one-way ANOVA with Tukey post hoc test. p values are indicated on the bars. n.s. non-significant
Rabbit Polyclonal Anti Phospho Serine Cdk Substrate Antibodies, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/rabbit polyclonal anti-phospho-serine cdk substrate antibodies/product/Cell Signaling Technology Inc
Average 90 stars, based on 1 article reviews
rabbit polyclonal anti-phospho-serine cdk substrate antibodies - by Bioz Stars, 2026-02
90/100 stars
  Buy from Supplier
anti phospho s t substrate kinase antibodies  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc anti phospho s t substrate kinase antibodies
Activation <t>of</t> <t>PKC</t> or CaMKII, but not <t>PKA,</t> is required for the accumulation of SENP1 at synapses. a Representative confocal images of time-lapse recordings of GFP-SENP1-expressing rat hippocampal secondary dendrites preincubated 10 min in TTX (0.5 µM) with JNJ16259685 (0.5 µM) and either the PKC antagonist Chelerythrine (5 µM), the CaMKII antagonist KN93 (1 µM) or the PKA inhibitor H89 (1 µM) and treated in the same medium for 25 min with DHPG (50 µM) as indicated. Scale bar, 5 µm. b Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.171 ± 0.010) and [Chelerythrine + DHPG + JNJ16259685] (1.004 ± 0.018) conditions. c Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.168 ± 0.012) and [KN93 + JNJ16259685 + DHPG] (1.008 ± 0.012) conditions. d Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.142 ± 0.014) and [H89 + JNJ16259685 + DHPG] (1.072 ± 0.011) conditions. Statistics: Ordinary one-way ANOVA with Tukey post hoc test. p values are indicated on the bars. n.s. non-significant
Anti Phospho S T Substrate Kinase Antibodies, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/anti phospho s t substrate kinase antibodies/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
anti phospho s t substrate kinase antibodies - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier
phospho protein kinase c pkc ser substrate  (Cell Signaling Technology Inc)
96
Cell Signaling Technology Inc phospho protein kinase c pkc ser substrate
Activation <t>of</t> <t>PKC</t> or CaMKII, but not <t>PKA,</t> is required for the accumulation of SENP1 at synapses. a Representative confocal images of time-lapse recordings of GFP-SENP1-expressing rat hippocampal secondary dendrites preincubated 10 min in TTX (0.5 µM) with JNJ16259685 (0.5 µM) and either the PKC antagonist Chelerythrine (5 µM), the CaMKII antagonist KN93 (1 µM) or the PKA inhibitor H89 (1 µM) and treated in the same medium for 25 min with DHPG (50 µM) as indicated. Scale bar, 5 µm. b Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.171 ± 0.010) and [Chelerythrine + DHPG + JNJ16259685] (1.004 ± 0.018) conditions. c Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.168 ± 0.012) and [KN93 + JNJ16259685 + DHPG] (1.008 ± 0.012) conditions. d Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.142 ± 0.014) and [H89 + JNJ16259685 + DHPG] (1.072 ± 0.011) conditions. Statistics: Ordinary one-way ANOVA with Tukey post hoc test. p values are indicated on the bars. n.s. non-significant
Phospho Protein Kinase C Pkc Ser Substrate, supplied by Cell Signaling Technology Inc, used in various techniques. Bioz Stars score: 96/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/result/phospho protein kinase c pkc ser substrate/product/Cell Signaling Technology Inc
Average 96 stars, based on 1 article reviews
phospho protein kinase c pkc ser substrate - by Bioz Stars, 2026-02
96/100 stars
  Buy from Supplier

Image Search Results


Effects of VAS compounds on the PKC/NOX downstream signaling pathway. ( A ) Washed platelets (3.6 × 10 8 cells/ml) were pre-incubated with DMSO (solvent control), VAS compounds (2–10 μM), or Ro 31-8220 (2 μM) following stimulation with PDBu (150 nM) to trigger platelet aggregation. ( B ) The statistical analysis in ( A ). ( C ) After the reaction, platelet lysates were directly collected, and then subjected to Western blotting. Specific antibodies were used to detect PKC, IKKβ, and p38 MAPK. ( D , E ) Luciferase/luciferin and FITC-P-selectin antibody were used to detect ATP release and P-selectin using a microplate reader and flow cytometry, respectively. Data ( B , D ) are presented as means ± S.E.M. ( n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001, compared with the DMSO (solvent control) group. Data ( C , E ) are presented as means ± SEM ( C , n = 4; E , n = 3). ***p < 0.001, compared with the resting group. ## p < 0.01 and ### p < 0.001, compared with the PDBu-treated (positive control) group. Comparisons were made by ANOVA.

Journal: Scientific Reports

Article Title: VAS2870 and VAS3947 attenuate platelet activation and thrombus formation via a NOX-independent pathway downstream of PKC

doi: 10.1038/s41598-019-55189-5

Figure Lengend Snippet: Effects of VAS compounds on the PKC/NOX downstream signaling pathway. ( A ) Washed platelets (3.6 × 10 8 cells/ml) were pre-incubated with DMSO (solvent control), VAS compounds (2–10 μM), or Ro 31-8220 (2 μM) following stimulation with PDBu (150 nM) to trigger platelet aggregation. ( B ) The statistical analysis in ( A ). ( C ) After the reaction, platelet lysates were directly collected, and then subjected to Western blotting. Specific antibodies were used to detect PKC, IKKβ, and p38 MAPK. ( D , E ) Luciferase/luciferin and FITC-P-selectin antibody were used to detect ATP release and P-selectin using a microplate reader and flow cytometry, respectively. Data ( B , D ) are presented as means ± S.E.M. ( n = 3). *p < 0.05, **p < 0.01, and ***p < 0.001, compared with the DMSO (solvent control) group. Data ( C , E ) are presented as means ± SEM ( C , n = 4; E , n = 3). ***p < 0.001, compared with the resting group. ## p < 0.01 and ### p < 0.001, compared with the PDBu-treated (positive control) group. Comparisons were made by ANOVA.

Article Snippet: The anti-phospho-(ser) PKC substrate and anti-phospho-p38 MAPK (Ser 180 /Tyr 182 ) polyclonal antibodies (pAbs) and anti-IKKβ and anti-p38 MAPK monoclonal antibodies (mAbs) were purchased from Cell Signaling (Beverly, MA, USA).

Techniques: Incubation, Western Blot, Luciferase, Flow Cytometry, Positive Control

Activation of PKC or CaMKII, but not PKA, is required for the accumulation of SENP1 at synapses. a Representative confocal images of time-lapse recordings of GFP-SENP1-expressing rat hippocampal secondary dendrites preincubated 10 min in TTX (0.5 µM) with JNJ16259685 (0.5 µM) and either the PKC antagonist Chelerythrine (5 µM), the CaMKII antagonist KN93 (1 µM) or the PKA inhibitor H89 (1 µM) and treated in the same medium for 25 min with DHPG (50 µM) as indicated. Scale bar, 5 µm. b Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.171 ± 0.010) and [Chelerythrine + DHPG + JNJ16259685] (1.004 ± 0.018) conditions. c Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.168 ± 0.012) and [KN93 + JNJ16259685 + DHPG] (1.008 ± 0.012) conditions. d Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.142 ± 0.014) and [H89 + JNJ16259685 + DHPG] (1.072 ± 0.011) conditions. Statistics: Ordinary one-way ANOVA with Tukey post hoc test. p values are indicated on the bars. n.s. non-significant

Journal: Cellular and Molecular Life Sciences

Article Title: Bidirectional regulation of synaptic SUMOylation by Group 1 metabotropic glutamate receptors

doi: 10.1007/s00018-022-04405-z

Figure Lengend Snippet: Activation of PKC or CaMKII, but not PKA, is required for the accumulation of SENP1 at synapses. a Representative confocal images of time-lapse recordings of GFP-SENP1-expressing rat hippocampal secondary dendrites preincubated 10 min in TTX (0.5 µM) with JNJ16259685 (0.5 µM) and either the PKC antagonist Chelerythrine (5 µM), the CaMKII antagonist KN93 (1 µM) or the PKA inhibitor H89 (1 µM) and treated in the same medium for 25 min with DHPG (50 µM) as indicated. Scale bar, 5 µm. b Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.171 ± 0.010) and [Chelerythrine + DHPG + JNJ16259685] (1.004 ± 0.018) conditions. c Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.168 ± 0.012) and [KN93 + JNJ16259685 + DHPG] (1.008 ± 0.012) conditions. d Histograms showing the mean GFP-SENP1 fluorescence intensity ± SEM in spines at the plateau (20–25 min of treatment) in control, [DHPG + JNJ16259685] (1.142 ± 0.014) and [H89 + JNJ16259685 + DHPG] (1.072 ± 0.011) conditions. Statistics: Ordinary one-way ANOVA with Tukey post hoc test. p values are indicated on the bars. n.s. non-significant

Article Snippet: Protein extracts (25 μg) were resolved by SDS-PAGE, transferred onto nitrocellulose membrane and immunoblotted with the following primary antibodies: Rabbit anti-SENP1 1/250 (Sigma-Aldrich Cat# HPA011765, RRID:AB_1079907); Mouse anti-PSD95 1/10000 (Antibodies Incorporated Cat# 75–028, RRID:AB_2292909); Mouse anti-Homer1 1/1000 (Synaptic Systems Cat# 160 003, RRID:AB_2631222); Mouse anti-Synapsin1a/b 1/1000 (Santa Cruz Biotechnology Cat# sc-376623, RRID:AB_11150313); Mouse anti-SOD2 1/2000 (Santa Cruz Biotechnology Cat# sc-137254, RRID:AB_2191808); Mouse anti-NOPP140 1/700 (Santa Cruz Biotechnology Cat# sc-374033, RRID:AB_10917069); Rabbit anti-Coilin 1/500 (Santa Cruz Biotechnology Cat# sc-32860, RRID:AB_2081431); Rabbit anti-GM130 1/500 (BD Biosciences Cat# 610823, RRID:AB_398142); Rabbit anti-GAPDH 1/10000 (Sigma-Aldrich Cat# G9545, RRID:AB_79620); Rabbit Phospho-(Ser) PKC Substrate 1/1000 (Cell Signaling Technology Cat#2261, RRID:AB_330310); Rabbit monoclonal Phospho-PKA Substrate 1/1000 (Cell Signaling Technology Cat#9624, RRID:AB_331817); Rabbit anti-ERK1/2 1/1000 (Cell Signaling Technology Cat# 4695, RRID:AB_390779); Rabbit anti-phosphoERK1/2 1/2000 (Cell Signaling Technology Cat# 4370, RRID:AB_2315112).

Techniques: Activation Assay, Expressing, Fluorescence